Filing Flows › Adaptive Biotechnologies (ADPT) › Q3 2025
Adaptive Biotechnologies (ADPT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Adaptive Biotechnologies (ADPT) reported revenue of $94.0M for the third quarter 2025 (Q3 2025), +102% from a year earlier and +60% from the quarter before. Operating margin was 10.9%, net earnings $9.5M (10.2% of revenue).
Adaptive Biotechnologies, Q3 2025: revenue $94.0M (+102% year over year), operating margin 10.9%, net earnings $9.5M, operating cash flow −$7.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $94.0M | +60% | +102% |
| Operating profit | $10.3M | — | — |
| Net earnings | $9.5M | — | — |
| Operating cash flow | −$7.1M | — | — |
What changed
Revenue was $94.0M in Q3 2025, up 102% year over year and up 60% from the previous quarter.
Operating profit was $10.3M, a 10.9% margin (up 81.2 points year over year). Total costs grew 6% against revenue growth of 102%. The fastest-growing cost line was Sales & marketing (+14%). Net earnings were $9.5M. The effective tax rate was 0.0%.
Operating cash flow was −$7.1M. Non-cash charges added back $4.0M of depreciation and amortization and $13.3M of share-based compensation. Working capital and other items used $33.9M. Capital expenditures of $409K exceeded it, leaving free cash flow of −$7.5M.
Questions
What was Adaptive Biotechnologies' revenue in the third quarter 2025?
Adaptive Biotechnologies (ADPT) reported revenue of $94.0M for the third quarter 2025 (Q3 2025), +102% from a year earlier and +60% from the quarter before.
Was Adaptive Biotechnologies profitable in the third quarter 2025?
Operating profit was $10.3M (10.9% of revenue) and net earnings $9.5M.